ProSomnus® Sleep Technologies Announces Record Revenues as it Emerges from Reorganization
ProSomnus Sleep Technologies, the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy provider, has announced record revenues for Q2 2024 as it emerges from reorganization. Key highlights include:
- Q2 revenues reached a record $9.1 million, up 22% from Q1 2024 and 31% year-over-year
- Year-to-date 2024 revenues totaled $16.6 million, a 30% increase over H1 2023
- Operating expenses decreased by 25% to $12.5 million year-to-date
- The company's Second Amended Plan of Reorganization closed on August 5, 2024, ensuring business continuity and recapitalization
CEO Len Liptak highlighted the company's resilience and growth during the reorganization process, emphasizing the value of their non-CPAP therapy and ongoing progress in key initiatives, including the ProSomnus RPMO2 Device.
ProSomnus Sleep Technologies, il principale fornitore di terapie per l'Apnea Notturna Ostruttiva (OSA) non CPAP, ha annunciato entrate record per il secondo trimestre del 2024 mentre emerge dalla riorganizzazione. I punti salienti includono:
- Le entrate del Q2 hanno raggiunto un record di 9,1 milioni di dollari, in aumento del 22% rispetto al Q1 2024 e del 31% rispetto all'anno precedente.
- Le entrate da inizio anno 2024 hanno totalizzato 16,6 milioni di dollari, un incremento del 30% rispetto al primo semestre del 2023.
- Le spese operative sono diminuite del 25% a 12,5 milioni di dollari da inizio anno.
- Il Secondo Piano di Riorganizzazione Modificato dell'azienda è stato concluso il 5 agosto 2024, garantendo continuità aziendale e ricapitalizzazione.
Il CEO Len Liptak ha sottolineato la resilienza e la crescita dell'azienda durante il processo di riorganizzazione, enfatizzando il valore della loro terapia non CPAP e i progressi continui in iniziative chiave, incluso il dispositivo ProSomnus RPMO2.
ProSomnus Sleep Technologies, el principal proveedor de terapia para la Apnea Obstructiva del Sueño (OSA) que no utiliza CPAP, ha anunciado ingresos récord para el segundo trimestre de 2024 mientras emerge de la reorganización. Los puntos destacados incluyen:
- Los ingresos del Q2 alcanzaron un récord de 9.1 millones de dólares, un aumento del 22% en comparación con el Q1 2024 y del 31% en comparación con el año anterior.
- Los ingresos acumulados hasta la fecha de 2024 totalizaron 16.6 millones de dólares, un aumento del 30% en comparación con el primer semestre de 2023.
- Los gastos operativos disminuyeron en un 25% a 12.5 millones de dólares hasta la fecha.
- El Segundo Plan Modificado de Reorganización de la empresa se cerró el 5 de agosto de 2024, asegurando la continuidad del negocio y la recapitalización.
El CEO Len Liptak destacó la resiliencia y el crecimiento de la empresa durante el proceso de reorganización, enfatizando el valor de su terapia no CPAP y el progreso continuo en iniciativas clave, incluido el Dispositivo ProSomnus RPMO2.
ProSomnus Sleep Technologies는 비-CPAP 폐쇄 수면 무호흡증(OSA) 치료 분야의 선두 제공업체로서 2024년 2분기 역대 수익을 발표했습니다. 이는 재편성 절차를 마치며 이루어진 성과입니다. 주요 하이라이트는 다음과 같습니다:
- 2분기 수익은 910만 달러로, 2024년 1분기 대비 22%, 전년 대비 31% 증가했습니다.
- 2024년 연간 수익 총계는 1660만 달러로, 2023년 상반기 대비 30% 증가했습니다.
- 운영 비용은 25% 감소하여 연간 1250만 달러에 달했습니다.
- 회사의 수정된 두 번째 재편성 계획은 2024년 8월 5일에 종료되어 비즈니스 연속성과 재자본화를 보장합니다.
CEO인 Len Liptak는 재편성 과정에서 회사의 회복력과 성장을 강조하며, 비-CPAP 치료의 가치와 ProSomnus RPMO2 장치를 포함한 주요 이니셔티브에서의 지속적인 진행을 강조했습니다.
ProSomnus Sleep Technologies, le leader des thérapies pour l'Apnée Obstructive du Sommeil (OSA) sans CPAP, a annoncé des revenus record pour le deuxième trimestre 2024 alors qu'elle sort d'une réorganisation. Les points clés comprennent :
- Les revenus du Q2 ont atteint un record de 9,1 millions de dollars, en hausse de 22% par rapport au Q1 2024 et de 31% d'une année sur l'autre.
- Les revenus cumulés depuis début 2024 s'élèvent à 16,6 millions de dollars, soit une augmentation de 30% par rapport au premier semestre 2023.
- Les dépenses d'exploitation ont diminué de 25% pour atteindre 12,5 millions de dollars depuis le début de l'année.
- Le second plan de réorganisation modifié de l'entreprise a été clôturé le 5 août 2024, garantissant la continuité de l'activité et la recapitalisation.
Le CEO Len Liptak a souligné la résilience et la croissance de l'entreprise durant le processus de réorganisation, en mettant l'accent sur la valeur de leur thérapie non CPAP et les progrès continus des initiatives clés, y compris le dispositif ProSomnus RPMO2.
ProSomnus Sleep Technologies, der führende Anbieter von nicht-CPAP Therapie für obstruktive Schlafapnoe (OSA), hat Rekordumsätze für das zweite Quartal 2024 bekannt gegeben, während das Unternehmen aus der Reorganisation hervorgeht. Zu den wichtigsten Highlights gehören:
- Die Umsätze im Q2 lagen bei 9,1 Millionen Dollar, was einem Anstieg von 22% im Vergleich zum Q1 2024 und 31% im Jahresvergleich entspricht.
- Die Umsatzsumme bis zum heutigen Datum 2024 betrug 16,6 Millionen Dollar, ein Anstieg von 30% gegenüber dem ersten Halbjahr 2023.
- Die Betriebskosten sanken um 25% auf 12,5 Millionen Dollar bis zum heutigen Datum.
- Der zweite geänderte Reorganisationsplan des Unternehmens wurde am 5. August 2024 abgeschlossen und sichert die Fortführung des Geschäfts sowie die Rekapitalisierung.
CEO Len Liptak hob die Widerstandsfähigkeit und das Wachstum des Unternehmens während des Reorganisationsprozesses hervor und betonte den Wert ihrer nicht-CPAP Therapie sowie die kontinuierlichen Fortschritte in wichtigen Initiativen, einschließlich des ProSomnus RPMO2 Geräts.
- Record Q2 2024 revenues of $9.1 million, up 22% from Q1 2024 and 31% year-over-year
- Year-to-date 2024 revenues increased by 30% to $16.6 million compared to H1 2023
- Operating expenses decreased by 25% year-to-date
- Successful completion of reorganization, ensuring business continuity and recapitalization
- Ninth consecutive quarter of record revenue growth
- None.
PLEASANTON, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- ProSomnus Sleep Technologies (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced record revenues for the quarter ended June 30, 2024 as it formally emerges from reorganization on August 5, 2024.
- Revenues for the second quarter totaled a record
$9.1 million reflecting increasing orders for the Company’s precision intraoral medical devices. These quarterly results reflect a22% increase over the first quarter of 2024, a31% increase over the same quarter in 2023 and the 9th record revenue quarter over the past 10 sequential quarters. - Year-to-date 2024 revenues totaled
$16.6M , a30% increase over the first half of 2023. - Operating expenses year-to-date decreased
25% to$12.5 million from$16.7 million . - Effective August 5, 2024, the transactions contemplated by the Second Amended Plan of Reorganization of ProSomnus, Inc. closed. The culmination of the plan results in:
- Uninterrupted continuation of the Company’s business;
- Ongoing delivery and support of the Company’s products;
- ProSomnus Sleep Technologies, Inc. emerging from reorganization; and
- Recapitalization of the Company and new capital investment to drive future growth and stability.
"The past several months have clearly demonstrated the resilience of ProSomnus and the value of our non-CPAP therapy” noted Len Liptak, Chief Executive Officer. "ProSomnus continued to serve its patients and sleep clinician customers through a harrowing time in our Company’s evolution. The continuous growth of our business as reflected in the financial results, ongoing and significant progress in key initiatives, including our ProSomnus RPMO2 Device, and our ability to attract new capital all while efficiently navigating the intricacies of our corporate reorganization is a reflection of the special nature of ProSomnus and our mission to be the leading provider of solutions to patients affected by OSA and the clinicians who care for them."
About ProSomnus Sleep Technologies
ProSomnus Sleep Technologies is the leading non-CPAP therapy for the treatment of Obstructive Sleep Apnea, a serious medical disease affecting over 1 billion people worldwide, that is associated with comorbidities including heart failure, stroke, hypertension, morbid obesity, and type 2 diabetes. ProSomnus intraoral medical devices are engineered to precisely track the treatment plan and anatomy for each patient. Non-invasive, patient preferred and easy to use, ProSomnus devices have demonstrated excellent efficacy, safety, adherence, and overall outcomes in a growing body of clinical investigations. ProSomnus precision intraoral devices are FDA-cleared, patented, and covered by commercial medical insurance, Medicare, TRICARE and many Government-sponsored healthcare plans around the world, representing over 200 million covered lives. To learn more, visit www.ProSomnus.com.
Contact
Heather Whalen
ProSomnus Sleep Technologies
Phone: +1.925.360.2990
Email: HWhalen@ProSomnus.com
FAQ
What were ProSomnus Sleep Technologies' Q2 2024 revenues?
How much did ProSomnus Sleep Technologies' operating expenses decrease in 2024?
When did ProSomnus Sleep Technologies emerge from reorganization?
What is ProSomnus Sleep Technologies' main product focus?
